Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) announced today that its shareholders have approved its combination with biotherapeutics firm Gelesis.
The deal was approved with a total of 24,835,281 votes in favor of the combination. A total of 25,643,831, or 74.3%, of CPSR’s issued and outstanding shares of common stock were present at yesterday’s special meeting. Although CPSR reached a high of $12.23 on January 10th, it quickly fell to a low of $6.06 today, and closed at $6.70.
The SPAC announced on Monday that all but $3.4 million have been removed from its trust via redemptions. A total of 27,260,179 shares were redeemed, including shares held by PIPE investors. Capstar noted that GCCU VI LLC and TOCU XXIX LLC redeemed 1,000,000 shares each, although each have also agreed to purchase 1,750,000 shares through the transaction’s PIPE. But, Capstar had already secured the deal’s completion in regards to its minimum cash condition by adding a backstop in late December.
Capstar also revised its agreement with Gelesis in early November in order to be re-struck on more investor-friendly terms. The changes slashed Gelesis’ proposed equity valuation by 25%, from $900 million to $675 million, in exchange for concessions on earnout shares and the sponsor’s promote.
The parties expect to close the deal shortly, and the combined company is expected to trade on the NYSE under the symbol “GLS”.
Capstar initially announced their combination on July 19. Boston-based Gelesis is advancing a series of therapies for weight management and chronic gut conditions with a consumer-facing approach.
ADVISORS
- Citi is serving as exclusive financial advisor to Gelesis
- Goodwin Procter LLP is serving as legal counsel to Gelesis.
- UBS Investment Bank is serving as exclusive financial and lead capital markets advisor to Capstar
- Kramer Levin Naftalis & Frankel LLP is serving as Capstar’s legal counsel.
- UBS Investment Bank and Citi are serving as private placement agents to Capstar with respect to the PIPE financing.
- Winston & Strawn LLP served as counsel to the placement agents.
- BTIG, LLC is also serving as a capital markets advisor to Capstar.
At the SPAC of Dawn It has clearly taken some time for SPACs to break out from their niche, but SPACs and de-SPACs are suddenly everywhere in current events. As the Russian invasion of Ukraine drags on, one of the most prolific SPAC teams has stepped forward with a letter of intent to take Ukraine’s...
Live Oak Acquisition Corp. V (NASDAQ:LOKVU) has filed for a $200 million IPO that brings another serial SPAC team back to the mix for a generalist search but with a pair of technology deals already in their pocket. The new S-1 also puts Santander on the board for the 2025 SPAC market after it made...
CH4 Natural Solutions (NYSE:MTNE.U) has filed for a $250 million SPAC to bring both the Riverstone sponsor team and underwriter Citigroup back to the market for 2025. The team secured notably sponsor-friendly terms for the vehicle and will not overfund its trust. In fact, along with fellow Friday filer Live Oak V (NASDAQ:LOKVU), these two...
At the SPAC of Dawn Amid a restive market, SPACs have front-loaded their business this week with three of their four votes set for today and tomorrow. One of these is a completion vote, in which Bowen (NASDAQ:BOWN) will try and secure shareholder approval for its combination with Shenzhen Qianzhi BioTechnology just after having gained...
Terms Tracker for the Week Ending January 10, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This was the first full week in January and the first non-holiday week since December 23rd. All the same, 2025 has started with a bang...